Statement of Principles concerning malignant neoplasm of the cerebral meninges (Reasonable Hypothesis) (No. 3 of 2018)

The central concept is malignant neoplasm of the cerebral meninges. The instrument defines it under section 7(2) as a primary malignant neoplasm arising from cells of the cerebral meninges. It expressly excludes soft tissue sarcoma, carcinoid tumour, non‑Hodgkin’s lymphoma, Hodgkin’s lymphoma and melanoma. This exclusion is significant because those other tumour types have separate Statements of Principles with their own factors; a claimant whose tumour is one of the excluded types cannot rely on this SoP even if the tumour is located near the meninges. The ICD‑10‑AM codes C70.0 and C70.9 are provided as a reference, but the instrument’s own definition governs, not the coding manual. The coding manual is the Tenth Edition effective 1 July 2017, published by the Independent Hospital Pricing Authority. Using ICD codes for administrative convenience does not override the clinical definition in subsection 7(2).

The reasonable hypothesis standard is the core evidentiary test for claims under section 120A of the VEA and section 338 of the MRCA. This SoP is made under subsection 196B(2), which is for the reasonable hypothesis standard, as opposed to subsection 196B(3) which applies to the reasonable satisfaction (balance of probabilities) standard for certain other diseases. The RMA determines that the factors in section 9 are the minimum necessary to raise a reasonable hypothesis. The instrument does not define “reasonable hypothesis” itself; that concept is derived from case law and legislation. However, the factors are intended to be grounded in sound medical‑scientific evidence, as stated in section 8. The RMA’s view is not binding on a court, but decision‑makers must apply the instrument unless it is set aside.

Another key concept is relevant service, defined in the dictionary to include operational service, peacekeeping service, hazardous service, British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA. The factor must be related to the relevant service rendered by the person (section 10). That means the mere existence of the factor is not enough; the factor itself must be attributable to the person’s service. For example, a veteran who received a cumulative equivalent dose of 0.1 sievert of ionising radiation to the brain must show that the exposure arose from service (such as from nuclear testing or medical procedures performed as part of service). Similarly, being overweight or obese for at least five years within the 20 years before clinical onset must be linked to service circumstances (e.g., service‑related diet, lack of exercise due to injury). This relationship requirement prevents a claimant from relying on factors that are purely civilian in origin.

Cumulative equivalent dose is defined in the dictionary with reference to the Australian Radiation Protection and Nuclear Safety Agency’s guide for calculating dose, excluding normal background radiation in Australia. The dose must be to the brain, not just whole‑body exposure, and must be at least 0.1 sievert. That threshold is met by examples such as being present at nuclear weapon tests, undergoing multiple CT scans, or flying frequently as aircrew. The note gives examples but they are not exhaustive.

Being overweight or obese means having a BMI of 25 or greater, calculated as weight in kilograms divided by height in metres squared. The factor requires that the person was overweight or obese for at least five years within the 20 years before clinical onset. The instrument does not require the five years to be continuous; it could be cumulative. The 20‑year window is the look‑back period. This factor is notable because it implicates common lifestyle conditions that may have no connection to service; the relationship requirement in section 10(1) will often be the battleground.

Pregnancy and postpartum status: the person must be in the second or third trimester or within 30 days postpartum at the time of clinical onset (or clinical worsening). This factor appears to be based on evidence that hormonal changes during late pregnancy and early postpartum may accelerate growth of meningiomas (the most common malignant neoplasm of cerebral meninges). However, the SoP does not require that the pregnancy occurred during service; it only requires that the pregnancy (and thus the hormonal state) be related to service. That would be rare for male veterans, but could apply to female veterans who became pregnant while on service or whose postpartum period occurred during service. The practical effect is narrow.

Drug treatment: “being treated with a drug as specified” is defined as receiving medroxyprogesterone acetate (≥15 mg/day for ≥1 year), cyproterone acetate (≥15 mg/day for ≥1 year), chlormadinone acetate (≥50 mg/day for ≥1 year), or megestrol acetate (≥50 mg/day for ≥1 year). These are progestogenic drugs used for various indications including contraception, endometriosis, and cancer treatment. The factor applies to both onset and worsening within ten years of such treatment. Again, the treatment must be related to service, meaning it was provided by Defence or under a Defence‑arranged health program.

Hormone replacement therapy (HRT) means administration of oestrogen preparations, often with progesterone, to offset hormone deficiency following surgically induced or naturally occurring menopause. The factor requires continuous use for at least six months before clinical onset, and if use has ceased, onset must occur within ten years of cessation. This is a standalone factor separate from the specified drug factor, though some HRT preparations may contain progestins. The relationship to service requirement will likely be difficult to establish unless the HRT was part of service‑provided healthcare.

Inability to obtain appropriate clinical management for malignant neoplasm of the cerebral meninges is a factor that applies only to clinical worsening (section 9(8)). This means the person already has the disease, and service‑related circumstances prevented them from receiving proper treatment, leading to aggravation. This factor is common in many SoPs and often arises when a veteran was posted to a remote location with inadequate medical services or was imprisoned as a prisoner of war.

Finally, “death from malignant neoplasm of the cerebral meninges” includes cases where a terminal event was contributed to by the disease. The terminal events listed are pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function. This broadening prevents disputes about proximate cause when the immediate cause of death is a complication of the primary cancer.

The primary persons affected are veterans, members of the Peacekeeping Forces, members of the Forces under the VEA, and members under the MRCA who have rendered relevant service. Relevant service includes operational service (active combat or similar), peacekeeping service, hazardous service (e.g., nuclear testing), British nuclear test defence service, warlike service, and non‑warlike service. The instrument also affects their dependents and legal personal representatives because death from the disease triggers compensation and dependant benefits. The SoP governs adjudication of claims by the Department of Veterans’ Affairs, the Veterans’ Review Board, the Administrative Appeals Tribunal, and the Federal Court. Decision‑makers must apply the factors to each claim; they cannot invent new factors or ignore the defined ones.

The instrument indirectly affects medical practitioners who diagnose and treat veterans, because the definition of malignant neoplasm of the cerebral meninges excludes certain tumours. Pathologists reporting on tumour type must be aware of the exclusions to avoid misclassification. For example, a diagnosis of primary cerebral lymphoma of the meninges is not covered; nor is melanoma arising in the meninges. The treating doctors may be asked to provide opinions on whether BMI met thresholds, whether pregnancy was in the relevant trimester, or whether drug treatment met the specified doses and duration.

The insurance industry is not directly affected because this is a statutory compensation scheme, not private insurance. However, workers’ compensation or income protection insurers may need to be aware of the SoP because a successful claim under the VEA or MRCA might affect entitlements under other schemes and create coordination issues. The instrument also affects the Repatriation Medical Authority itself, which is required to review and revoke earlier SoPs and issue new ones when medical evidence changes.

The broader public is affected only to the extent that the SoP influences government expenditure. Factors such as being overweight or obese and using HRT are common in the general population. If the relationship to service requirement is not stringently enforced, the SoP could expand the pool of eligible claimants and increase costs. Conversely, if the relationship requirement is applied strictly, few claimants will succeed on those factors. The instrument therefore shifts risk between the veteran population and the taxpayer.

Legal practitioners advising veterans need to understand the precise definitions and exclusions. They must also consider section 11, which cross‑references other SoPs: if a factor in section 9 refers to an injury or disease covered by another SoP (such as “inability to obtain appropriate clinical management” for another condition), then that other SoP must be applied. This creates a network of interlocking instruments.

The SoP itself imposes no duties on individuals; it is a legislative instrument that defines an evidentiary standard. However, it creates a right for a claimant to have their claim assessed under the factors in section 9. If a claimant raises one or more of those factors and the factor is related to their relevant service, then a reasonable hypothesis is raised, and the decision‑maker must accept that the disease is service‑related unless the hypothesis is disproved beyond reasonable doubt (under section 120(1) of the VEA). The right is procedurally important: it shifts the evidentiary burden to the decision‑maker.

The RMA has a duty under the VEA to determine Statements of Principles based on sound medical‑scientific evidence. Section 8 of the instrument recites the RMA’s view that such evidence exists. The RMA also has a duty to revoke earlier instruments when they are superseded, as happened here. The Commissioner or decision‑maker has a duty to apply the SoP correctly, including ensuring the factor is related to service. Section 10 makes clear that each factor must be related to the person’s relevant service. That is a substantive duty of assessment.

For clinical worsening factors (subsections 9(6) to 9(8)), the instrument provides that they apply only where the disease was suffered or contracted before or during (but did not arise out of) the person’s service. That is, the person already had the disease before the relevant service, or it first appeared during service without being caused by service. In such cases, the factor must have made a material contribution to worsening. The duty of decision‑makers is to distinguish between onset and worsening carefully.

The instrument does not confer any right to compensation directly; that is found in the VEA and MRCA. But without this SoP, a claim could not succeed unless the disease was accepted as service‑related under the general law. The SoP effectively codifies what evidence is sufficient. Claimants have a right to know the factors and to attempt to meet them. They also have a right to challenge the SoP’s validity on legal grounds (e.g., that the RMA exceeded its power or that the factors are not supported by sound medical‑scientific evidence). That right is not in the instrument but in administrative law.

This instrument does not contain any penalty provisions. It is not a regulatory instrument that imposes fines or sanctions. Enforcement occurs through the claim adjudication process. If a claimant or adviser fabricates evidence to meet a factor, they may be liable for fraud under the Criminal Code or under specific provisions of the VEA concerning false statements. The VEA contains offences for obtaining benefits dishonestly, but those are not part of this SoP.

The practical enforcement of the SoP is by decision‑makers who must refuse a claim if no factor is present. If a factor is present but the relationship to service is not established, the claim must also be refused. The Veterans’ Review Board and Administrative Appeals Tribunal review refusals. The Federal Court can review decisions for legal error, including misapplication of the SoP. There is no monetary penalty for non‑compliance by the RMA; the remedy would be judicial review of the instrument itself. A person affected could argue that the SoP was made without proper evidence or that it is unreasonable, though such challenges are rare and face significant deference.

The instrument revokes the earlier 2009 SoP, effective 29 January 2018. That revocation is a form of enforcement of the RMA’s duty to keep SoPs current. Non‑enforcement of the old SoP is automatic; claims made after that date must be assessed under the new one.

This instrument is a delegation from the VEA, specifically under section 196B(2). It operates within the framework of the VEA and the MRCA. It does not replace the underlying test for reasonable hypothesis but provides a structured set of factors. Section 120A of the VEA directs that a claim shall not be determined unless the RMA has determined a SoP, and then the claim is to be assessed by reference to the SoP. So this instrument is a mandatory consideration for all claims for malignant neoplasm of the cerebral meninges.

The instrument interacts with other SoPs through section 11. If a factor in section 9 refers to an injury or disease for which another SoP exists (for example, “inability to obtain appropriate clinical management” may refer to a completely different condition), then that other SoP’s factors must be applied. This ensures consistency across the SoP system. Also, the dictionary definitions rely on external documents: the ARPANSA guide for cumulative equivalent dose and the ICD‑10‑AM coding manual. Those documents are incorporated by reference as in force on specified dates (2 August 2017 for ARPANSA; 1 July 2017 for ICD‑10‑AM). Changes to those external documents after those dates do not automatically affect this SoP; the RMA would need to amend or revoke the instrument.

The MRCA is referenced throughout. The SoP applies to claims under section 338 of the MRCA, which is the analogous provision to section 120A of the VEA. This means a single SoP covers two different compensation regimes, reducing duplication.

State workers’ compensation laws and common law tort claims are not directly affected, but a veteran who receives compensation under the VEA or MRCA after using this SoP may be barred from suing the Commonwealth or others. That interaction is external to the instrument.

The instrument recites that it revokes the Statement of Principles concerning malignant neoplasm of the cerebral meninges No. 21 of 2009, as amended. That earlier instrument was also made under subsection 196B(2) and (8) of the VEA. The 2009 SoP was in force for about eight and a half years before being replaced by this 2018 instrument. The instrument does not state what changes were made, but the dictionary and factors would have been updated based on new medical evidence. The 2018 version includes specific drug names and dose thresholds, a BMI definition, and a refined definition of cumulative equivalent dose referencing the ARPANSA guide from 2 August 2017. The earlier SoP likely had different thresholds or omitted some factors. The revocation is automatic; there is no transitional provisions in the instrument. Claims that were lodged before 29 January 2018 but not yet determined would have been assessed under the 2009 SoP unless a new instrument applied retrospectively? The general rule under the VEA is that the SoP in force at the time of the claim decision applies, not at the time of lodgement. So the transitional effect is that for claims determined after 29 January 2018, the 2018 SoP is used, even if the claim was lodged before that date. This could affect claimants who had gathered evidence under the old factors.

There have been no further amendments noted in the source; this is the current version as of the instrument’s date (22 December 2017, effective 29 January 2018). However, it may have been amended later, but the source does not mention any. For the purposes of this analysis, we take the instrument at face value.

The source document does not mention any litigation history. No cases are cited. However, it is a matter of public record that Statements of Principles have been challenged in the Federal Court and High Court, often on grounds that the RMA did not base a factor on sound medical‑scientific evidence or that the instrument exceeded the power granted by the VEA. For example, cases like Repatriation Commission v. Deledio (1998) and Repatriation Commission v. Gosewinkel (1999) established the test for “reasonable hypothesis” and the role of SoPs. More recently, the High Court in Repatriation Commission v. Hill (2002) addressed the standard of review. But no specific case is mentioned for this particular disease or this particular instrument number. It is possible that a claimant unsuccessfully argued that the BMI threshold is arbitrary, or that the 0.1 sievert threshold is too high, but without source citations we cannot assert that.

We can note that any litigation would likely focus on the relationship to service requirement, especially for factors like being overweight or obese or using HRT. The difficulty of proving that such common conditions are service‑related may lead to disputes. Also, the definition of “being treated with a drug as specified” is very specific; a claimant who took a different progestin or a lower dose may challenge the exclusion. The instrument’s rigidity could be grounds for judicial review if a claimant argues that the RMA should have included other drugs based on current evidence. However, the RMA has a wide discretion, and courts are reluctant to substitute their own view.

Several subtle features can trap unwary claimants and advisers. First, the definition of malignant neoplasm of the cerebral meninges excludes soft tissue sarcoma, carcinoid tumour, non‑Hodgkin’s lymphoma, Hodgkin’s lymphoma and melanoma. If a biopsy report uses a different histology, or if the pathologist labels the tumour as “meningeal sarcoma” or “primary meningeal lymphoma”, the claim cannot use this SoP. The exclusion is absolute even if the tumour is in the meninges. Claimants need to check the exact diagnosis against the list. Second, the ICD code reference is only for administrative convenience; the definition in subsection 7(2) controls. A hospital record that codes the disease as C70.0 without specifying histology might be insufficient if the tumour is actually one of the excluded types.

Third, being overweight or obese requires a BMI of 25 or greater. The instrument does not define “for at least five years within the 20 years before the clinical onset.” The phrase “within the 20 years” could be interpreted as any five‑year period (not necessarily consecutive) that falls within the 20‑year window. But a claimant who had a BMI of 25 for only three years total would not meet the factor. Also, the relationship to service requirement: if a veteran was overweight due to postwar civilian life, that factor will fail. The factor itself does not create a presumption of service connection; the decision‑maker must find a causal link between service and being overweight. For example, a veteran who developed a metabolic condition from service‑related injury or medication might succeed, but simple overeating after discharge will not.

Fourth, the ionising radiation factor requires at least 0.1 sievert cumulative equivalent dose to the brain. That threshold is relatively low (equivalent to about 10 CT scans of the head), but the dose must be calculated using the ARPANSA guide. Many veterans may have received lower doses from medical X‑rays or from occupational exposure. The guide excludes normal background radiation but includes medical procedures. If a veteran had many X‑rays during service but the dose to the brain is hard to reconstruct, they may need expert evidence. The factor also requires at least five years between exposure and clinical onset; that is straightforward.

Fifth, the drug treatment factor specifies four progestogenic drugs with exact dose and duration thresholds. A veteran who took a different progestin (e.g., norethisterone) or a lower dose (e.g., medroxyprogesterone acetate 10 mg per day) will not meet the factor even if the drug is similar. The factor does not account for drug combinations or intermittent use. “Continuous period of at least one year” means daily or near‑daily use; missed doses could break continuity. Similarly, hormone replacement therapy requires “continuous period of at least six months.” The instrument does not define continuous, but a gap of a few days might be acceptable; longer gaps would break continuity.

Sixth, the pregnancy factor only applies to being in the second or third trimester or within 30 days postpartum at the time of clinical onset (or worsening). This means early pregnancy (first trimester) is not covered. Also, the factor applies only to females (implicitly), but the instrument does not limit it by gender. In rare cases, transgender veterans could be affected if they were pregnant. The relationship to service requirement: the pregnancy itself must be related to service. For most female veterans, pregnancy is a personal event not caused by service, unless they became pregnant while on deployment and the service contributed to the timing. This factor will be extremely difficult to use.

Seventh, the inability to obtain appropriate clinical management factor (section 9(8)) applies only to clinical worsening, not onset. So a veteran who could not get treatment for an existing disease can claim worsening, but cannot use this factor to establish the original diagnosis as service‑related.

Eighth, the dictionary definition of “terminal event” includes pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function. This list is exhaustive, not illustrative, despite the use of “includes.” If death is caused by something else (e.g., pulmonary embolism, renal failure) that was contributed to by the disease, it may not be covered. Claimants should argue that the listed events are examples, but the wording “means the proximate or ultimate cause of death and includes the following” suggests the list is inclusive; but the five items are the only ones explicitly mentioned, and “includes” generally enlarges rather than limits. However, the note in the dictionary says “terminal event means…” and then lists five causes; the word “includes” may imply others are within the definition. This ambiguity could be litigated.

Ninth, the instrument uses “being overweight or obese” (BMI≥25) but does not account for muscular individuals who have a high BMI due to lean mass. A veteran bodybuilder with BMI 28 is technically overweight, but the medical evidence might not support the same risk. However, the SoP is a rule of thumb; it does not permit individualised exceptions unless challenged.

Tenth, the relationship requirement in section 10(1) applies to all factors. That means even if a factor is satisfied (e.g., the person has a BMI of 25 for five years in the 20‑year window), the decision‑maker must still be satisfied that the factor is related to the person’s relevant service. This is often the hardest hurdle. For example, a veteran who was overweight due to poor diet after discharge cannot succeed, whereas a veteran whose weight gain was caused by service‑related psychological medication might.

Finally, section 11 cross‑references other SoPs. If a factor like “inability to obtain appropriate clinical management for malignant neoplasm of the cerebral meninges” itself depends on the veteran having another disease that is covered by another SoP, then that other SoP must be used. This can complicate claims involving multiple conditions.

For claimants and their representatives, compliance means gathering medical evidence that establishes one or more of the eight factors and then showing how that factor relates to service. The specific steps are:

1. Obtain a confirmed diagnosis of malignant neoplasm of the cerebral meninges, excluding the excluded tumour types. A pathology report that clearly states the histology is essential. If the report uses ICD‑10‑AM code C70.0 or C70.9 without histology, ask the treating doctor to clarify that it is not one of the excluded cancers.

2. For the ionising radiation factor: collect service records showing exposure to ionising radiation, such as deployment to nuclear test sites, involvement in nuclear weapon accidents, service as a dental or medical X‑ray technician, or aircrew flying at high altitudes. Obtain a dose reconstruction from ARPANSA or an expert using the ARPANSA guide to calculate the cumulative equivalent dose to the brain. The dose must be at least 0.1 Sv, and the exposure must have occurred at least five years before clinical onset.

3. For being overweight or obese: obtain medical records showing BMI measurements over time. Show that the person had a BMI of 25 or greater for a total of at least five years within the 20 years before the onset of the disease. Link the weight gain to service factors: e.g., injury‑related immobility, service‑induced mental health conditions leading to overeating, or medication side effects. Simply being overweight from civilian habits will not suffice.

4. For pregnancy factor: for female veterans, document the dates of pregnancy and postpartum period and confirm that the clinical onset or worsening occurred in the second or third trimester or within 30 days postpartum. The pregnancy must have occurred during service or been caused by service (e.g., if the veteran became pregnant while on active duty and the pregnancy was directly related to service circumstances). This will be rare.

5. For drug treatment factor: obtain pharmacy records or medical records showing the person received medroxyprogesterone acetate (≥15 mg/day continuous for ≥1 year), cyproterone acetate (≥15 mg/day), chlormadinone acetate (≥50 mg/day), or megestrol acetate (≥50 mg/day). The drug must have been prescribed by a service doctor or during service‑related treatment. The treatment must have occurred within the ten years before clinical onset (or worsening).

6. For hormone replacement therapy: document continuous use of oestrogen‑based HRT for at least six months before clinical onset. If use ceased, the onset must be within ten years of cessation. The HRT must have been provided in connection with service (e.g., service‑related menopause, such as from surgical removal of ovaries due to service injury).

7. For inability to obtain appropriate clinical management: this factor applies only to worsening. Demonstrate that after the disease was diagnosed, the person was unable to receive proper treatment because of service‑related circumstances (e.g., remote posting, incarceration as POW, lack of medical resources due to service). This cannot be used to establish the original onset.

8. For death claims: if the person died from a terminal event contributed to by the disease, provide evidence linking the disease to the terminal event (e.g., pneumonia caused by immunosuppression from tumour treatment).

Decision‑makers must check that each claimed factor is objectively present and then rigorously apply section 10(1): is the factor related to the person’s relevant service? That may require evidence from the veteran’s service records and medical history. If the factor is present but not service‑related, the claim must fail. The decision‑maker should not assume that because a factor exists, it is ipso facto service‑related.

Compliance with the instrument also means using the correct definitions. For example, when assessing BMI, the decision‑maker must use the formula W/H² and take the person’s weight and height at the relevant times. If the person had bariatric surgery, the pre‑surgery BMI is relevant if the five‑year period fell before surgery.

The instrument is not ambiguous on most points, but where it is (e.g., “terminal event” inclusive or exhaustive), decision‑makers should apply the ordinary meaning and consider the policy intent. Ultimately, the claim will succeed only if a reasonable hypothesis is raised and not disproved. The instrument is the gateway; the destination is still the full statutory test under the VEA or MRCA.